Floatz logo

Eloxatin

SAR445877

M.D. Anderson Cancer CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the SAR445877 cohort.

Asset / SponsorPhaseRating
Irinotecan
M.D. Anderson Cancer Center
Phase 1CC
FLUOROURACILUM
M.D. Anderson Cancer Center
Phase 1CC
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 1CC
Calcium folinate pentahydrate
M.D. Anderson Cancer Center
Phase 1CC
sar445877
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →